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Background
Recombinant Adeno-associated virus (rAAV) based
vectors recently emerged as very promising candidates
for viral gene therapy due to a large toolbox available
including twelve different AAV serotypes, natural iso-
lates, designer capsids and library technologies [2].
Furthermore, rAAV vectors have favourable properties
such as non-pathogenicity of AAV, low B-/T-cell immu-
nogenicity against transgenes delivered and long-term
transgene expression from a non-integrating vector
[5,9]. Promising data from clinical trials using rAAV-
based vectors for the treatment of e.g. haemophilia or
retinal diseases as well as the recent approval of the first
gene therapy drug in the European Union, Glybera® to
treat lipoprotein lipase deficiency, emphasise the poten-
tial of rAAV vectors for gene therapy approaches in a
wide variety of indications [8,7,15]. Thereby, the demand
for robust and cost-effective manufacturing of those vec-
tors for market supply rose steadily. Standard produc-
tion systems comprise transient transfection- and/or
infection-based approaches using mammalian cells [3],
or insect cells [16]. However, high production costs
combined with considerable regulatory effort and safety
concerns gave rise to the development of producer cell
lines enabling stable rAAV production [3].
AAVs are parvoviruses whose productive infection is
depending on the presence of helper viruses like e.g.
adenovirus (AdV). Their single-stranded DNA genome
carries two genes. The rep gene encodes proteins respon-
sible for site-specific integration, viral genome replication
as well as packging. The cap gene is translated into three
structural proteins building the capsid shelf. Furthermore,
cap encodes a protein required for capsid assembly (AAP
or assembly-activating protein) that has been described
recently [13]. The AAV genes are flanked by inverted
terminal repeat (ITR) sequences constituting the replica-
tion, integration and packaging signal. In a stable produ-
cer cell line with integral helper functions, all required
genetic elements are stably integrated into the genome of
the host cell as independent expression constructs: the
recombinant vector implying a transgene flanked by AAV
ITRs, the AAV genes rep and cap required for replication
and encapsidation, as well as adenoviral helper function
delivered by sequences encoding genes E1a, E1b, E2a,
E4orf6 and viral associated (VA) I/II RNA [9]. In a timely
regulated fashion, viral proteins are expressed and the
AAV genome is replicated and encapsidated. As some of
the gene products arising during rAAV production are
toxic, an inducible expression of the gene products is
indispensable for generation of stable production cells.
The aim of the underlying study is to provide all tools
necessary to generate a stable and versatile producer cell
line In order to circumvent the problems triggered by
toxic proteins inevitably arising during rAAV formation,
one objective of the project is to establish stable produ-
cer cells where rAAV production can be induced by
temperature shift at the final production scale. To begin
with, we first performed some general feasability studies
to investigate whether the generation of stable and indu-
cible producer cell lines using proprietary constructs is a
viable approach. For this purpose, experiments for
rAAV manufacturing based on a transient packaging
approach were conducted. Infection of rep, cap and
rAAV vector plasmid transfected cells with wildtype
Adenovirus was compared with co-tranfection of the
cells with additional plasmids carrying the Adenoviral
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helper genes. The influence of different cultivation tem-
peratures on Adenovirus replication kinetics and rAAV
productivity in the transient packaging approaches were
analyzed. Furthermore, we investigated differential gene
expression in response to temperature downshifts.
Results
In the first experiments, a transfection-/infection-based
approach was chosen to produce rAAV. For this, HeLa
cells were co-transfected with three plasmids encoding
the AAV vector on one side and the rep and cap genes
delivered on two separate constructs on the other side
(trans-split packaging system, [6]). Subsequently, cells
were infected with a helper virus. Cultivation of cells at
32 °C post infection resulted in significantly increased
rAAV titres compared to 37 °C (Figure 1A). This could
arise from an arrest of cells in G2/M phase, causing
enhanced growth but decreased proliferation. Hence, cells
exhibit enlarged size and elevated protein production,
possibly supported by avoided degradation of rDNA as
previously described for CHO cells [14]. Repressed ade-
noviral replication kinetics may trigger prolonged cellular
viability and, thereby, further increase rAAV titres. In fact
these results also suggest that high copy numbers of
helper genes are not essential for efficient rAAV packa-
ging being an important prerequisite for the generation
of efficient producer cells by stable integration of only
few copies of the Adenoviral helper genes. Importantly,
rAAV production was also possible replacing the adeno-
virus infection step by co-transfection of rep-, cap- and
rAAV vector transfected HeLa cells with two more
plasmids coding for all known adenoviral helper genes.
Considering that in such an approach cells have to be
co-transfected by five different plasmids at the same time
in order to produce rAAV, the yiels obtained in this
“transfection only approach” were quite promising. Over-
all rAAV yields generated with the rep/cap trans-split
packaging system [6] could be further increased by modi-
fications of the rep and cap coding sequences in terms of
avoidance of production of non-functional byproducts
(Figure 1B).
Differential gene expression analysis of HeLa cells cul-
tivated at different temperatures gave rise to the identifi-
cation of three genes up-regulated up to 7-fold and 16
miRNAs likely regulated more than 2-fold at lowered
temperature (Table 1). Underlying genetic switches are
subject to further investigations. Appropriate tempera-
ture-inducible switches will be used to control expres-
sion of the adenoviral helper gene E1a, the key inducer
of the whole cascade required for rAAV production.
Applied in stable producer cells, such a system would
allow for timely-regulated induction of rAAV produc-
tion. Making use of a temperature shift as primary
switch for rAAV production, we would combine the
inevitable induction event with conditions presumably
enhancing rAAV production.
Conclusions
Taken together, these first data provide the basis for a
successful generation of temperature inducible stable
Figure 1 (A) Transfection- and infection-based generation of rAAV in HeLa cells at different temperatures. Cells were transfected by
calcium phosphate using three plasmids encoding the rAAV vector, rep and cap, followed by AdV5 infection and subsequent incubation of the
cells at three different temperatures. Genomic rAAV titers were determined 96 h post infection as previously described [4]. (B) Investigation of
rAAV production in a “transfection only approach"applying plasmids encoding rep, cap, vector as well as adenoviral E1 and remaining AdV
helper functions. Different variants of rep and cap were compared regarding rAAV productivity. 1: Approach implying functionally separated rep
and cap genes on different plasmids, which are devoid of rep78 expression and lack an artificial Rep Binding Site (RBS) in the pUC19 plasmid
backbones [6] (standard plasmids used in all preceding experiments). 2: Same rep and cap plasmids but modified to avoid the expression of
non-functional and truncated viral gene products by deletion of various promoter and potential transcription start sites. Genome titre was
analyzed 120 h post infection as previously described [4].
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producer cells carrying all genetic elements required for
rAAV production. A versatile and high-titre rAAV pro-
duction platform based on such cells will be applicable
for industrial-scale manufacturing and thus has the
potential to open AAV-based gene therapy to a high
number of patients.
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Table 1 Analysis of differential gene expression in HeLa









Gene A 30°C Up 3.2-fold 6.9-
fold
Gene B 30°C Up 2.2-fold 2.6-
fold




32°C Up 3.1-fold -
miRNA
B
32°C Down 3.3-fold -
miRNA
C
32°C Up 3.0-fold -
Cells were seeded at two different densities and cultivated at 37°C for two
days. Subsequently, cells were incubated for another 6 hours at 30, 32, and
37°C, respectively, before mRNA was isolated from the cells. Microarray
analysis (GeneChip® Human Exon 1.0 ST Array, Affymetrics) was performed to
identify mRNAs differentially expressed more than 2-fold. Validation was done
by RT qPCR analysis (EvaGreen® Mastermix, Biorad) and included controls of
regulated and non-regulated mRNAs [12,11,1]. Differentially expressed miRNAs
(>2-fold) were also identified by microarray analysis (GeneChip® miRNA 2.0
Array, Affymetrics). As validation is not yet completed, only an excerpt of the
most promising miRNA candidates is shown.
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